|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPIL1 |
Gene summary for PPIL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPIL1 | Gene ID | 51645 |
| Gene name | peptidylprolyl isomerase like 1 | |
| Gene Alias | CGI-124 | |
| Cytomap | 6p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024RCX8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51645 | PPIL1 | LZE2T | Human | Esophagus | ESCC | 1.22e-02 | 7.29e-01 | 0.082 |
| 51645 | PPIL1 | LZE4T | Human | Esophagus | ESCC | 6.01e-12 | 2.59e-01 | 0.0811 |
| 51645 | PPIL1 | LZE5T | Human | Esophagus | ESCC | 1.13e-02 | 3.66e-01 | 0.0514 |
| 51645 | PPIL1 | LZE7T | Human | Esophagus | ESCC | 9.12e-03 | 1.82e-01 | 0.0667 |
| 51645 | PPIL1 | LZE20T | Human | Esophagus | ESCC | 1.01e-02 | 1.37e-01 | 0.0662 |
| 51645 | PPIL1 | LZE22T | Human | Esophagus | ESCC | 4.31e-03 | 3.13e-01 | 0.068 |
| 51645 | PPIL1 | LZE24T | Human | Esophagus | ESCC | 3.61e-11 | 1.77e-01 | 0.0596 |
| 51645 | PPIL1 | LZE6T | Human | Esophagus | ESCC | 8.77e-04 | 3.20e-01 | 0.0845 |
| 51645 | PPIL1 | P1T-E | Human | Esophagus | ESCC | 1.58e-02 | 1.54e-01 | 0.0875 |
| 51645 | PPIL1 | P2T-E | Human | Esophagus | ESCC | 3.04e-34 | 6.61e-01 | 0.1177 |
| 51645 | PPIL1 | P4T-E | Human | Esophagus | ESCC | 2.19e-33 | 8.82e-01 | 0.1323 |
| 51645 | PPIL1 | P5T-E | Human | Esophagus | ESCC | 1.77e-20 | 4.43e-01 | 0.1327 |
| 51645 | PPIL1 | P8T-E | Human | Esophagus | ESCC | 5.34e-19 | 2.74e-01 | 0.0889 |
| 51645 | PPIL1 | P9T-E | Human | Esophagus | ESCC | 6.70e-08 | 2.23e-01 | 0.1131 |
| 51645 | PPIL1 | P10T-E | Human | Esophagus | ESCC | 5.72e-23 | 3.42e-01 | 0.116 |
| 51645 | PPIL1 | P11T-E | Human | Esophagus | ESCC | 1.02e-13 | 5.36e-01 | 0.1426 |
| 51645 | PPIL1 | P12T-E | Human | Esophagus | ESCC | 1.19e-29 | 5.12e-01 | 0.1122 |
| 51645 | PPIL1 | P15T-E | Human | Esophagus | ESCC | 4.50e-18 | 3.32e-01 | 0.1149 |
| 51645 | PPIL1 | P16T-E | Human | Esophagus | ESCC | 2.56e-19 | 4.19e-01 | 0.1153 |
| 51645 | PPIL1 | P17T-E | Human | Esophagus | ESCC | 4.33e-09 | 5.23e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
| GO:00004131 | Liver | HCC | protein peptidyl-prolyl isomerization | 31/7958 | 42/18723 | 3.83e-05 | 3.80e-04 | 31 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPIL1 | SNV | Missense_Mutation | novel | c.208N>G | p.Thr70Ala | p.T70A | Q9Y3C6 | protein_coding | deleterious(0.02) | possibly_damaging(0.594) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| PPIL1 | SNV | Missense_Mutation | c.313N>T | p.Pro105Ser | p.P105S | Q9Y3C6 | protein_coding | deleterious(0.01) | possibly_damaging(0.682) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL1 | SNV | Missense_Mutation | c.7N>A | p.Ala3Thr | p.A3T | Q9Y3C6 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL1 | SNV | Missense_Mutation | rs568130003 | c.349N>A | p.Ala117Thr | p.A117T | Q9Y3C6 | protein_coding | deleterious(0.04) | possibly_damaging(0.649) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPIL1 | SNV | Missense_Mutation | novel | c.308N>T | p.Ala103Val | p.A103V | Q9Y3C6 | protein_coding | deleterious(0) | benign(0.39) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| PPIL1 | SNV | Missense_Mutation | novel | c.164N>T | p.Arg55Ile | p.R55I | Q9Y3C6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| PPIL1 | SNV | Missense_Mutation | c.455G>A | p.Arg152His | p.R152H | Q9Y3C6 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPIL1 | SNV | Missense_Mutation | c.7N>A | p.Ala3Thr | p.A3T | Q9Y3C6 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| PPIL1 | SNV | Missense_Mutation | c.455N>A | p.Arg152His | p.R152H | Q9Y3C6 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPIL1 | SNV | Missense_Mutation | novel | c.134N>A | p.Arg45Gln | p.R45Q | Q9Y3C6 | protein_coding | tolerated(0.06) | benign(0.1) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |